Research shows cancer treatment progresses with ferritin nanocages, indicating further clinical applications may be needed.
While HFn nanocages show strong promise in vaccine development, their application in cancer treatment faces significant translational challenges. These include limited human data, variability in receptor expression, rapid clearance, and the need for more representative models and scalable manufacturing, though certain untargeted HFn-based systems as Gd-HFn and Dox-HFn appear closer to clinical readiness.
No takes yet. Share an insight, caveat, or question.
Giacobbo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: